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ABSTRACT 
 
Linoleic acid, with a DRI of 12-17g/d, is the most highly consumed polyunsaturated fatty 
acid in the Western diet and is found in virtually all commonly consumed foods.  The concern 
with dietary linoleic acid, being the metabolic precursor of arachidonic acid, is its consumption 
may enrich tissues with arachidonic acid and contribute to chronic and overproduction of 
bioactive eicosanoids. However, no systematic review of human trials regarding linoleic acid 
consumption and subsequent changes in tissue levels of arachidonic acid has been undertaken.  
In this study, we reviewed the human literature that reported changes in dietary linoleic acid and 
its subsequent impact on changing tissue arachidonic acid in erythrocytes and plasma/serum 
phospholipids. We identified, reviewed, and evaluated all peer-reviewed published literature 
presenting data outlining changes in dietary linoleic acid in adult human clinical trials that 
reported changes in phospholipid fatty acid composition (specifically arachidonic acid) in 
plasma/serum and erythrocytes within the parameters of our inclusion/exclusion criteria. 
Decreasing dietary linoleic acid up to 90% was not significantly correlated with changes in tissue 
arachidonic acid levels (p=0.39). Similarly, when dietary linoleic acid levels were increased six 
fold, no significant correlations with tissue arachidonic acid levels were observed (p=0.72). 
However, there was a positive relationship between dietary gamma-linolenic acid and 
arachidonic acid on changes in tissue arachidonic levels. Our results do not support the concept 
that modifying current intakes of dietary linoleic acid has an effect on changing tissue levels of 
arachidonic acid in adults consuming Western-type diets. 
 
 
 
 
 
  
 
v 
 
 
 
 
TABLE OF CONTENTS 
 
LIST OF TABLES ........................................................................................................................vi 
LIST OF FIGURES......................................................................................................................vii 
ABBREVIATIONS.................................................................................................................... viii 
Introduction ....................................................................................................................................1 
1.1 Dietary Lipids: Digestion, Absorption and Transportation .......................................2 
1.2 Essential Fatty Acids..................................................................................................3 
1.3 Polyunsaturated Fatty Acids ......................................................................................4 
1.4 Dietary n-6 PUFA and Tissue Arachidonic Acid ......................................................5 
Arachidonic Acid Cascade...............................................................................................7 
Eicosanoids ......................................................................................................................7 
Cyclooxygenase pathway.................................................................................................8 
1.6 Inflammation..............................................................................................................9 
1.5 CVD .........................................................................................................................10 
1.7 Cancer ......................................................................................................................11 
1.8 Dietary Linoleic Acid and Tissue Arachidonic Acid...............................................12 
1.9  Research Objective .................................................................................................15 
2. Discussion ................................................................................................................................35 
3. Summary and Conclusions.......................................................................................................41 
REFERENCES.............................................................................................................................44 
APPENDIX ..................................................................................................................................66 
VITA ............................................................................................................................................74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
vi 
 
 
 
 
 
 
 
 
LIST OF TABLES 
 
Table 1.  Studies outlining the effects of decreasing dietary linoleic acid levels (% energy) from 
baseline on changes in plasma/serum phospholipid arachidonic acid content ............................25 
Table 2.  Studies outlining the effects of supplementing dietary linoleic acid levels (g/day) on 
changes in plasma/serum phospholipid arachidonic acid content................................................28 
Table 3.  Studies outlining the effects of supplementing dietary linoleic acid levels (g/day) on 
changes in plasma/serum phospholipid arachidonic acid content................................................31 
Table 4.  Studies outlining the effects of supplementing dietary gamma-linolenic acid on changes 
in plasma/serum phospholipid arachidonic acid content. ............................................................33 
Table 5.  Studies outlining the effects of supplementing dietary arachidonic acid on changes in 
plasma/serum phospholipid arachidonic acid content..................................................................34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
vii 
 
LIST OF FIGURES 
 
Figure 1. N-6 metabolic pathway...................................................................................................6 
Figure 2. Arachidonic acid cascade. ..............................................................................................8 
Figure 3. Schematic outlining the systematic review...................................................................21 
Figure 4: Effects of decreasing dietary linoleic acid (LA) intake (% change) based on energy on 
changes in plasma/serum phospholipid arachidonic acid (AA) content. .....................................67 
Figure 5: Effects of increasing dietary linoleic acid (LA) intake (% change) based on energy on 
changes in plasma/serum phospholipid arachidonic acid (AA) content. .....................................68 
Figure 6: Effects of increasing dietary linoleic acid (LA) intake (g/d) on changes in 
plasma/serum phospholipid arachidonic acid (AA) content. ....................................................... 69 
Figure 7: Effects of increasing dietary linoleic acid (LA) (% change) intake based on energy on 
changes in erythrocyte (RBC) phospholipid arachidonic acid (AA) content. .............................70 
Figure 8: Effects of decreasing dietary linoleic acid (LA) (% change) based on energy on 
changes in erythrocyte (RBC) phospholipid arachidonic acid (AA) content. ............................. 71 
Figure 9: Effects of increasing dietary gamma-linolenic acid (GLA) (mg/d) on changes in 
plasma/serum phospholipid arachidonic acid (AA) content. ....................................................... 72 
Figure 10: Effects of increasing dietary arachidonic acid (AA) (% change) based on energy on 
changes in plasma/serum phospholipid AA content. ...................................................................73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
viii 
 
 
ABBREVIATIONS 
 
 
 
 
AA  Arachidonic acid 
AI Adequate intake 
CVD Cardiovascular disease 
DRI Dietary reference intake 
EFA Essential fatty acid 
ER Endoplasmic reticulum 
GLA Gamma linolenic acid 
LA Linoleic acid 
TAG Triacylglycerol 
PL Phospholipid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
1 
 
 
Chapter 1 
 
Introduction 
 
 
 
 
 
 
 
 
  
 
2 
 
 
1.1 Dietary Lipids: Digestion, Absorption and Transportation  
Triacylglycerols (TAG), followed by phospholipids (PL), are the major source of dietary 
lipids in the human diet.  Digestion of lipids begins in the mouth with partial hydrolysis of  sn-3 
fatty acids of TAG by lingual lipase (1), and subsequently by gastric lipase in the stomach. 
Along with gastric lipase, the stomach aids digestion with gastric grinding and the result is a 
mixture of  emulsified components containing lipids and the enzymatic products (2). The 
emulsion enters the small intestine where digestion of lipids continues.  Pancreatic lipase (in the 
presence of colipase) cleaves fatty acids from the sn-1 and sn-3 positions of TAG (2). 
Phospholipids are acted upon by pancreatic phospholipase A2 at the sn-2 position generating free 
fatty acids (typically a polyunsaturated fatty acid) and lysophospholipids. Cholesterol esters are 
acted upon by cholesteryl esterase forming free fatty acids and unesterified cholesterol.  
In order for these hydrophobic products of digestion to be absorbed by intestinal mucosal 
cells, they have to become sufficiently soluble within the aqueous environment to cross the 
unstirred water layer (3). For this to happen, aggregates of fatty acids, cholesterol, 
lysophospholipids and monoacylglycerides are combined with bile salts and acids to form 
micelles (10-12). 
 These small emulsified aggregates of lipid products transverse the unstirred water layer 
and are absorbed by enterocytes passively or by active transport. The active transporter for fatty 
acids, FATP4, is responsible for absorption when concentrations of fatty acids are low (4), but at 
high concentrations, diffusion is the predominant mechanism. After absorption, fatty acids are 
delivered to the endoplasmic reticulum (ER) of the enterocyte via fatty acid binding proteins (5)  
where they are re-esterified into TAG, cholesterol esters and phospholipids. Along with 
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cholesterol and apoproteins, these lipid components are incorporated into chylomicrons for 
transport in the general circulation (6).  
The fatty acids from the TAG of the chylomicrons are delivered to extrahepatic tissues 
via the action of lipoprotein lipase (through the generation of two free fatty acids and a 
monoacylglycerol). Loss of TAGs results in remodeling of the chylomicron where surface 
components containing phospholipids, cholesterol and cholesterol esters form the backbone of 
other lipoproteins (i.e., high density lipoproteins), resulting in a chylomicron remnant that is 
subsequently cleared by the liver. The liver either uses (metabolizes) these lipid components or 
repackages them with endogenously synthesized lipids from the endoplasmic reticulum into very 
low density lipoproteins (VLDL) for delivery to extrahepatic tissue. While in the plasma, the 
TAGs from the VLDL can follow a similar metabolic path as that of the chylomicron.  The 
resulting remnant can pick up cholesteryl esters from high density lipoproteins in its conversion 
to low density lipoproteins or be cleared by receptors in the liver. The re-circulated lipids 
associated with lipoproteins are the source of fatty acids for plasma phospholipids and represent 
those lipids derived from the endoplasmic reticulum of hepatocytes (7, 8).   
1.2 Essential Fatty Acids. 
Evidence for the essentiality of certain types of fats emerged in the early 1900’s 
when a lipid-deficiency disease was reported in rodents. Rodents fed lipid-free diets 
developed clinical symptoms such as hindered growth, weight loss and dermatitis (9). 
Dermatitis is a skin condition that typically exhibits  red, scaly skin and dandruff, and can 
manifest itself with dermal lesions (9). Feeding a lipid source, i.e. lard, rescinded these 
symptoms and restored growth. From this experiment, it appeared that dietary fat, like 
vitamins, played a unique role in supporting basic physiological systems. However, lard 
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contains a variety of saturated, monounsaturated and polyunsaturated fatty acids and 
necessitated research with other oils and individual fatty acids to discern the curative effects. 
In subsequent studies, corn oil and linseed oil also alleviated the symptoms, while butter and 
coconut oil failed to do so (10). Further work found that feeding linoleic acid (LA) and 
arachidonic acid (AA), in isolation, cured these clinical symptoms, although a lower amount 
of AA was needed (11).  
The rodent observations of essential fatty acids resembled human observations. 
Confirmation of deficiency symptoms were seen in adult males given LA-deficient 
intravenous therapy, and LA-containing oils alleviated these symptoms (12). Similarly, 
evidence emerged when infants receiving intravenous therapy developed similar EFA-
deficiency symptoms and they also were cured with methyl-linoleate (13). These combined 
results suggested a common requirement of LA for rodents and humans.  
1.3 Polyunsaturated Fatty Acids 
            Essential fatty acids belong to a larger family, called polyunsaturated fatty acids (PUFA). 
PUFA are a group of fatty acids that have more than one double bond (14).  They are divided 
into several families, depending upon the location of the terminal double bond closest to the 
methyl end, i.e., double bonds located 3, 6, or 9 carbons from the terminal methyl carbon These 
families are non-interconvertible, since mammals lack the ability to introduce double bonds 
beyond the ninth carbon from the carboxylic acid end (15).  One of the families is the n-6 fatty 
acids. The designation for this family is due to the terminal double bond at the sixth carbon from 
the methyl end. Of all the dietary PUFAs, the n-6 family is consumed in the greatest amount in 
the Western diet (16). 
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1.4 Dietary n-6 PUFA and Tissue Arachidonic Acid 
The parent compound of n-6 PUFA family is LA (18:2n-6). LA is ubiquitous in nearly all 
commonly consumed foods in the Western diet and is also the predominant PUFA in foods 
(60%-100% of total PUFA content in virtually all commonly consumed foods). LA is found in 
the highest concentrations in vegetable oils, nuts and legumes, although significant amounts are 
also found meat, eggs and animal products. Once consumed, LA and other n-6 PUFAs can be 
delivered to tissues, as described previously, and in incorporated into the sn-2 position of 
phospholipids by a variety of acyltransferases (17). Following consumption, LA can also be 
converted to downstream n-6 fatty acids following the action of delta-6 desaturase (Figure 1). 
This enzyme is the rate-limiting step in the formation of more highly unsaturated fatty acids. LA 
is converted to gamma-linolenic acid (GLA, 18:3 n-6) via the delta-6 desaturase, which is 
immediately elongated to di-homo-gamma-linolenic acid (DGLA, 20:3 n-6) with the addition of 
two carbons by an elongase. AA (20:4n-6) is formed from DGLA via the action of delta-5 
desaturase, with the addition of a double-bond between the 5th and 6th carbons.  
Of these n-6 PUFA, LA and AA are preferentially incorporated into membrane 
phospholipids. Phospholipids are polar lipids that form the non-hydrophilic barrier of the cell 
membrane. Their unique properties are a result of a hydrophilic head, containing a phosphoester 
bond linked to a charge (choline, serine, inositol, ethanolamine) and two hydrophobic fatty acid 
tails, attached by ester bonds. The sn-1 position is reserved for saturated and monounsaturated 
fatty acids, and the sn-2 position is reserved for PUFA(18). The remodeling of fatty acid 
composition of phospholipids is carried out by a variety of  acyltransferases, which incorporate 
fatty acids into the sn-1 and sn-2 positions (19). With constant remodeling (incorporation, 
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release, re-incorporation), there appears to competition for  the sn-2 position among various 
PUFAs fatty acids, whereby LA and AA compete for incorporation (20).    
Tissue phospholipids are responsive to dietary lipid intake following delivery of these 
lipids via the various circulating lipoproteins. Some tissue phospholipids respond more acutely to 
dietary PUFA (such as plasma phospholipids), while others exhibit more long term exposure, 
i.e., erythrocytes  (21, 22). Erythrocytes are formed in the bone marrow with a life span of 120 
days and the fatty acids found in these phospholipids represent a more stable pool of dietary 
PUFA compared to the plasma phospholipid pool (23, 24)  
 
 
LA
GLA
DGLA
AA
Delta 6 Desaturase
Elongase
Delta 5 Desaturase
Vegetable 
oils, meats
Specialty oils
Meats, fish,
eggs
 
Figure 1. N-6 metabolic pathway. A series of enzymatic steps converts linoleic acid to highly 
unsaturated n-6 derivatives.  
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Arachidonic Acid Cascade 
AA is a major PUFA associated with membrane phospholipids. When released from 
phospholipids via a variety of phospholipases, AA can be enzymatically oxidized to hundreds of 
bioactive derivatives called eicosanoids. The formation of these compounds are collectively 
referred to as the AA cascade and are mediated by a group of enzymes called cyclooxygenases 
(COXs) and lipoxygenases (LOXs), as well as enzymes associated with the cytochrome P450 
system (Figure 2).    
Eicosanoids 
Eicosanoids are bioactive lipid compounds (eicosa- means 20) derived from highly 
unsaturated fatty acids with a length of 20 carbons, i.e. AA. The first eicosanoids were 
discovered from the seminal fluid of the prostate gland with smooth cell muscle relaxing 
properties and were termed “prostaglandins” (25-28). Subsequent research demonstrated that 
there were many prostaglandin-like compounds (29-31).  In 1964, it was discovered that AA was 
the parent compound of these prostaglandins (32). 
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Figure 2. Arachidonic acid cascade. AA is converted to eicosanoids through lipoxygenase 
(LOX), cyclooxygenase (COX), and cytochrome P450 pathways. 
Cyclooxygenase pathway 
Prostaglandins are produced by the action of cyclooxygenase (COX) and are 
characterized by the addition of two molecules of oxygen forming a distinct endoperoxide ring. 
There are two isoforms, COX-1 and COX-2. COX-1 is constitutively expressed at relatively low 
levels in all tissues, and in some tissues is the only isoform, i.e., platelets. It has been identified 
to be important in a number of tissues. For example,  it is involved in maintaining the integrity of 
the gastric mucosa (33), modulation of renal blood flow (34), and regulation of platelet 
aggregation (35). In contrast, COX-2 is the inducible isoform. It is expressed following 
stimulation of growth factors and proinflammatory cytokines, and as such, is the target of a 
number of selective COX-2 inhibitors such as Celebrex® (36). COX-2 is involved in 
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inflammation, cancer and cardiovascular disease (CVD) and increases in response to injury. The 
COXs are the committed steps for the conversion of AA to prostaglandin (PG)H2, the parent 
compound to the 2-series prostaglandins (i.e., PGE2), thromboxane (TXA2) and prostacyclin 
(PGI2) (37).  
The LOXs are a family of lipid oxygenases that incorporate molecular oxygen on AA at 
specific sites forming lipid peroxide derivatives (38). If the oxygen is attached at carbon 5, it is 
referred to as a 5-LOX. If it incorporates oxygen at carbon 12, it is a 12-LOX, carbon 15, a 15-
LOX, and so. The LOX pathways produce a variety of proinflammatory eicosanoids (39). 5-
LOX is responsible for the formation of leukotrienes (LTs), such as LTB4, LTC4, LTD4, LTE4 
(40).
 
 They are potent inflammatory mediators produced by a variety of tissues. LTB4 is a key LT 
produced by leukocytes that is involved in activation of neutrophils (41), while the cysteinyl 
leukotrienes (LTC4, LTD4, LTE4) are key mediators of asthma and anaphylaxis. Even vascular 
tissue, such as the aorta produces LOX products that along with leukocytes are believed to be 
critical for the progression of cardiovascular disease (42, 43) 
1.6 Inflammation 
Inflammation is a biological response to injury. Immune cells contribute to this response 
in a variety of ways, among them through the production of bioactive eicosanoids, such as PGs, 
LTs and TXA2 and are a target for anti-inflammatory therapies, such as non-steroidal anti-
inflammatory drugs (NSAIDs) (i.e., aspirin, Celebrex). Chronic and over-production of 
eicosanoids have been linked to arthritis, inflammatory bowel disease, atherosclerosis, chronic 
hepatitis, liver cirrhosis, asthma and psoriasis (44-48). Arachidonic acid is of interest because it 
is the precursor for the inflammatory eicosanoids and a number of recent reviews have outlined 
the role of dietary lipids and eicosanoids in inflammation and the immune response (47-51). 
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These reviews highlight the importance of antagonizing AA metabolism as a targeted 
intervention for treatment. Since tissue AA content influences inflammation, LA is thought to 
influence inflammatory biomarkers by enriching the AA pool (48), and therefore, contribute to  
inflammation in tissues (52).  However, the link between LA and inflammatory biomarkers has 
not been substantiated and increasing levels of LA may in fact reduce inflammation (53, 54)  
Therefore, there appears to be contradictory evidence regarding the link between LA and AA-
mediated inflammation.  
1.5 CVD 
 A variety of eicosanoids are implicated in the pathogenesis of CVD and involves 
platelets, endothelial cells, macrophages, erythrocytes, mast cells, neutrophils, granulocytes, 
lymphocytes and vascular smooth muscle cells (55, 56). Platelets are key initiators and 
promoters in this process (57) and tissue AA content is positively associated with TXA2 
production (a pro-aggregatory eicosanoid) and platelet aggregation (58, 59).  When activated, 
platelets produce TXA2 and in turn recruit and activate surrounding platelets, resulting in 
vasoconstriction, platelet vascular wall interaction, the release of cysteinyl leukotrienes, more 
TXA2 production and a plethora of a molecules (i.e., chemokines) that activate and recruit 
monocytes, leukocytes and lymphocytes, key mediators of vascular inflammation (57, 60, 61).  
Inhibition of platelet vascular wall interaction reduces atherosclerotic lesion formation (62), and 
inhibition of platelet COX activity is believe to be an underlying mechanism for the anti-
atherogenic effects of NSAIDs, such as aspirin (63).  
Following recruitment of monocytes to the subendothelium, activation/transformation of 
macrophages generate reactive oxygen species, tissue factor procoagulants, proinflammatory 
cytokines and a variety of eicosanoids via the 5-, 15-LOX and COX-2 pathways (56, 64). 
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Increased expression of 15-LOX is believed to be involved in oxidation of LDL (56, 65). 
Enrichment of macrophages with AA significantly increases the production of eicosanoids in 
general (14, 66), promoting the atherogenic process.  
These data linking AA metabolism and cardiovascular disease provides some concern as 
to the link between its precursor LA and risk. If dietary LA were to be converted to AA and 
further enrich tissues with AA, this could contribute to the disease process. However, a recent set 
of reviews suggest that LA may reduce risk of CVD (67, 68). 
1.7 Cancer 
Inflammation is an underlying mechanism linked to many cancers i.e. hepatitis, 
inflammatory diseases of the bowel (69-73), and bioactive lipids from the AA cascade are key 
mediators of inflammation. In particular, COX-2 and its downstream AA product, PGE2, has 
singled out as a key cancer promoter (74). Wang and Dubois elegantly describe how COX-2 and 
PGE2 in particular are involved in proliferation, immuno-suppression, angiogenesis, apoptosis 
and metastasis and invasion (75). Overexpression of COX-2 is a characteristic of many 
malignancies (76-78) and inhibition or down regulation of this enzyme attenuates tumorigenesis 
(79, 80). It is believed that PGE2 is the key mediator in this process (81). PGE2 induces intestinal 
epithelial cell proliferation and COX-2 expression in adenomas in mice with a defect in the Apc 
gene (mutation of an early gene involved in human colorectal cancer) (82). Similarly, expression 
of 15-prostaglandin dehydrogenase and the ability to degrade PGE2 is reduced in tumors 
compared to normal tissue (78). Coupled with over expression of COX-2, enriching tissues with 
AA would augment PGE2 levels and enhance its protumorigeneic activity. This was observed 
when ApcMin/+ mice were treated with PGE2 (83). 
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In support of these results, inhibition of the conversion of LA to prostaglandins, through 
AA, attenuates tumorigenesis (79, 84-86). This is particularly important from a diet perspective. 
Antagonism of AA metabolism (either with NSAIDs or long chain omega-3 fats) inhibits 
tumorigenesis, and by-passing these inhibitions restores tumor load. For example, the omega-3 
fatty acid EPA may reduce tumor load by attenuating AA content, and therefore the AA cascade 
(85). Most importantly is that the AA cascade is restored with dietary AA, even when fed 
alongside EPA (87). Critically important to this discussion is the fact that selectively inhibiting 
delta-6 desaturase in mice fed a diet containing LA, reduced tumor number by 35%, while the 
concomitant addition of AA with the inhibitor had no effect as compared to controls (88). These 
data are consistent with the extensive literature outlining the protective effects of NSAIDs on 
colorectal cancer (89, 90). 
1.8 Dietary Linoleic Acid and Tissue Arachidonic Acid 
LA is the sole contributor to tissue AA in the absence of other dietary n-6 PUFA. This 
was first demonstrated in rodent studies. When rodents were fed lipid-deficient diets, a non-
linear, dose-dependent enrichment of tissue AA occurred with increasing levels of dietary LA.  
In these studies, the diets were devoid of other PUFA, essential and non/conditionally-essential, 
that could contribute to the maintenance of physical properties required for normal cell function 
(i.e., membrane fluidity). In compensation, this could potentially exacerbate the rate and extent 
of this conversion. However, in the presence of other PUFA with similar properties, such as long 
chain n-3 PUFA, this relationship becomes more complicated in that they can be a suitable 
replacement for AA in tissues. Therefore, providing rodents with diets containing only LA may 
demonstrate that LA can and is metabolized to AA, eventually reaching a threshold (11), but the 
ability to quantitatively extrapolate these results to humans is uncertain. 
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In humans, LA is the major dietary PUFA in the Western diet at 12-17 grams per day for 
women and men, respectively (91), or approximately 6% of energy. The consumption of  LA 
coincides with the commercialization and availability of vegetable oils (92). This intake is 
complemented by consumption of other PUFA where each PUFA family competes for 
metabolism and incorporation into membrane phospholipids. If n-6 PUFA is the predominant 
family, then the fatty acids from this family should theoretically dominate membrane 
phospholipids.  
The minimum requirement for dietary LA has been estimated to be less than 2% of 
energy in humans (13, 93), and the levels of LA in the diet to achieve essentiality in infants could 
be as low as 0.5% of energy (13, 94). In adults, it has been reported that tissue levels of AA no 
longer change in response to increasing dietary amounts of LA above 2% energy (95). However, 
others report changes at higher intakes of LA (96). As a result, these n-6 rich diets conjure up 
unwanted scenarios of dose-dependent enrichment of tissues with AA and subsequent chronic 
and over-production of bioactive eicosanoids (97, 98). Proponents of this view recommend 
reducing LA levels (97, 99); however, there is little clarity as to what those levels should be. 
Some recommend consumption of LA be limited to less than 2% of energy (100), while other 
suggest any reductions can be beneficial (97, 98, 101).  
The recommendation of limiting LA to less than 2% was most likely based on the 
evidence that AA content in neutrophils was correlated with LA only when those intakes were 
below 2% of energy, where higher intakes had no effect (95). Similar evidence was shown in 
plasma cholesterol esters where AA content was unaffected by increasing intakes of LA at levels 
greater than 2% (102). Furthermore, a number of studies reported inverse relationships with 
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dietary LA and changes in tissue AA content (103, 104).With these discrepancies, controversy 
exists as to whether dietary LA does influence tissue AA content. 
In summary, there is little dispute in the literature that when LA intake is consumed at 
levels less than 2% energy there may be a positive relationship between dietary intake and 
changes in tissue AA content. However, will this relationship be observed when those levels are 
above 2% energy? Furthermore, since the current levels of dietary LA has been estimated to be 
approximately 6% of energy, and this essential fatty acid is typically consumed within a matrix 
of other PUFA, should the general public be concerned? 
With the conflicting evidence, compounded by pundits who proclaim an unmistakable 
link between dietary LA and tissue AA levels, the controversy regarding this issue continues. 
Recent review articles state that “the higher concentrations of LA typically found in the Western 
diet results in a greater conversion of LA to arachidonic acid” (105). Therefore as a result, 
“excessive n-6 precursors promotes formation of AA...high  intakes of n-6 PUFA may contribute 
to development of neuroinflammation” (106).  Even more pronounced statements describe the 
potential consequences of increased LA in the Western diet: 
Because of the increased amounts of omega-6 fatty acids in the Western diet, the 
eicosanoid metabolic products from AA, specifically prostaglandins, thromboxanes, 
leukotrienes, hydroxy fatty acids, and lipoxins, are formed in larger quantities… Thus, a 
diet rich in omega-6 fatty acids shifts the physiological state to one that is prothrombotic 
and proaggregatory, with increases in blood viscosity, vasospasm, and vasoconstriction 
and decreases in bleeding time..; (101).  
 
In summary, pundits proclaim the detrimental impact of increase dietary LA on tissue 
AA, and therefore chronic diseases.  Interestingly, no one has systematically reviewed the 
relationship between dietary LA and changes in tissue AA content, particularly within the 
context of a Western diet.  
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1.9  Research Objective 
The objective of this study was to explore the relationship between dietary LA and 
changes in tissue AA content within the context of a Western-type diet. This objective will be 
accomplished via the following specific aims: 
 
1. To determine if changes in LA consumption are correlated with changes in AA content of 
phospholipids in plasma/serum and erythrocytes in studies where subjects are consuming, for the 
most part, diets reflective of those in the general population.   
 
2. If dietary LA does not modify tissue AA levels, determine if that effect is the result of tissue 
saturation of AA or inhibition of conversion of LA to AA.
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Chapter 2 
 
 
 
 
Increasing Dietary Linoleic Acid Does Not Increase Tissue Arachidonic Acid Content in 
Adults Consuming Western-Type Diets 
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ABSTRACT 
 
Background: Linoleic acid, with a DRI of 12-17g/d, is the most highly consumed 
polyunsaturated fatty acid in the Western diet and is found in virtually all commonly consumed 
foods.  The concern with dietary linoleic acid, being the metabolic precursor of arachidonic acid, 
is its consumption may enrich tissues with arachidonic acid and contribute to chronic and 
overproduction of bioactive eicosanoids. However, no systematic review of human trials 
regarding linoleic acid consumption and subsequent changes in tissue levels of arachidonic acid 
has been undertaken. Objective: In this study, we reviewed the human literature that reported 
changes in dietary linoleic acid and its subsequent impact on changing tissue arachidonic acid in 
erythrocytes and plasma/serum phospholipids. Design: We identified, reviewed, and evaluated 
all peer-reviewed published literature presenting data outlining changes in dietary linoleic acid in 
adult human clinical trials that reported changes in phospholipid fatty acid composition 
(specifically arachidonic acid) in plasma/serum and erythrocytes within the parameters of our 
inclusion/exclusion criteria. Results: Decreasing dietary linoleic acid up to 90% was not 
significantly correlated with changes in tissue arachidonic acid levels (p=0.39). Similarly, when 
dietary linoleic acid levels were increased six fold, no significant correlations with tissue 
arachidonic acid levels were observed (p=0.72). However, there was a positive relationship 
between dietary gamma-linolenic acid and arachidonic acid on changes in tissue arachidonic 
levels. Conclusions: Our results do not support the concept that modifying current intakes of 
dietary linoleic acid has an effect on changing tissue levels of arachidonic acid in adults 
consuming Western-type diets. 
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Introduction 
Arachidonic acid (AA) is a potent bioactive molecule. When released from membrane 
phospholipids, it is converted to a variety of bioactive compounds, called eicosanoids.  These 
oxidized lipid molecules are related to a number of chronic diseases including cardiovascular 
disease, cancer and inflammation (48, 75, 107, 108). Enrichment of AA in tissues is positively 
correlated with the production of eicosanoids. Linoleic acid (LA) is the major dietary 
polyunsaturated fatty acid (PUFA) in the Western diet and is a metabolic precursor to AA, linked 
biochemically via two desaturases and an elongase. Typical intakes of LA are 12-17 grams per 
day for women and men, respectively (91), or approximately 6% of energy. In the absence of 
other n-6 PUFA (including dietary AA), dietary LA is the sole contributor to tissue AA. This 
relationship had been established in experimental rodent models where dietary LA was 
correlated with tissue AA content in a non-linear relationship in rats provided fat-free 
background diets (109) and lipid-rich diets (110). 
Recent reviews suggest this relationship may exist in adult humans consuming a typical 
Western-type diet (105, 106) and some have recommended limiting LA intake as a way to help 
reduce tissue AA levels (97, 101). Certainly, this relationship had been reported in subjects 
consuming diets containing LA at levels less than 2% of energy (95). There are, however, a 
number of recent papers suggesting that increasing dietary LA does not increase tissue AA 
levels, but in fact may have an inverse relationship (111, 112). To compound the complexity of 
this relationship, the family of n-6 PUFA are, in general, synonymously identified to dietary LA, 
while seemingly ignoring other members who can contribute to tissue AA, i.e., dietary gamma-
linolenic acid (GLA) and AA. 
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This study was designed to explore the relationship of dietary LA and tissue AA. This is 
the first study to review the literature as to whether increasing dietary LA is positively correlated 
with increasing tissue AA content, and whether reducing dietary LA has the opposite effect in 
adults consuming Western-type diets. We further investigated what potential contributions other 
dietary n-6 PUFA may have on tissue AA content. This study was limited in scope and did not 
address other controversial issues related to dietary PUFA or their health effects.  
Methods 
The aim of this paper was to identify, review, and evaluate all peer-reviewed published 
literature presenting data outlining changes in dietary LA in adult human clinical trials which 
report changes in phospholipid fatty acid composition (specifically AA) in plasma/serum and 
erythrocytes. Further refinements to the search strategy included reported changes in tissue AA 
levels following changes in dietary intake of AA and its various n-6 PUFA precursors, i.e., LA 
and GLA. Published articles meeting eligibility criteria from 1970 to present were reviewed, of 
which 4336 articles were retrieved from May 2009 - November 2009. The primary search engine 
used was PubMed.gov (The National Library of Medicine, National Institutes of Health), along 
with several prominent nutrition-based clinical journals, i.e., American Journal of Clinical 
Nutrition, British Journal of Nutrition, and any additional citations in articles reviewed. The 
search terms included linoleic acid, γ-linolenic acid, gamma-linolenic acid, arachidonic acid, 
omega-6, n-6, olive oil, soybean oil, sunflower oil, safflower oil, corn oil, omega-3, n-3, plasma, 
erythrocyte, red blood cell and phospholipid. After an initial review of the papers, 4043 were 
excluded because of insufficient data or studies that did not investigate our parameters. Of the 
293 papers that passed the initial review process, each was reviewed by two independent 
investigators (BR and JW) and thirty-six were acceptable by both reviewers. Those papers that 
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were not accepted (n=249) were rejected because baseline data was not sufficiently reported, 
data for target tissues was not presented, insufficient data was present and did not allow for 
appropriate calculations, background diets were not sufficiently described, or they included 
supplementation of restricted food items (i.e., long chain n-3 PUFA). 
The following eligibility criteria applied to all accepted articles. Subjects had to be 18 
years or older with no known metabolic disorder that would influence tissue AA content. 
Sufficient data on LA, GLA and/or AA consumption (pre- and post-intervention) was required. 
The nature of the intervention (i.e., capsules, oils or dietary modifications) had to be presented. 
The fatty acid data (plasma/serum and/or erythrocyte) had to be determined from fasting patients, 
pre- and post-supplementation.  Baseline and post-treatment tissue phospholipid fatty acid 
composition had to be provided. On occasion, percent changes in tissue fatty acid composition 
were provided and this data was used. Only those papers published after 1970 due to improved 
gas chromatographic methods were accepted.  Articles were automatically excluded if subjects 
were less than 18 years old, pregnant or nursing, consuming supplements containing long chain 
n-3 fatty acids or supplemented fish intake above and beyond their typical dietary regimen, or 
using known inhibitors of AA metabolism, such as non-steroidal anti-inflammatory drugs 
(NSAIDs). Thirty-six articles were found to meet all of the inclusion-exclusion criteria. 
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Articles accepted (36) 
Review of papers by two 
reviewers for relevance and 
inclusion (293) 
Articles that included baseline 
diet and/or supplementation 
amount and phospholipid data 
(293)
Articles retrieved from 
electronic sources (ex. 
PUBMED, AJCN, BJN etc..) 
and references  (4336) Articles not accepted due 
to insufficient or missing 
data;  or otherwise not 
suitable for our research 
objective (4043)
Articles not accepted by both 
reviewers because of design 
flaws, lack of sufficient data 
(dietary PUFA or tissue) or 
failing inclusion/exclusion 
criteria. (Supplementation of 
long-chain n-3 PUFA or fish/fish 
oil; data for target tissues not 
presented i.e. CE changes but not 
PL; PL species but not total PL) 
(249)
 
Figure 3. Schematic outlining the systematic review 
 
Once accepted, data on dietary n-6 fatty acid intake (% of calories or g/d) and tissue AA 
content were extracted. Study design, number and gender of subjects, method of supplementation 
(i.e., type of oil, capsules or food component used) were recorded. Those studies involving 
dietary LA as percentage of calories or g/d and its effects on changes in tissue AA content are 
summarized in Tables 1-3.  Similarly, those studies involving dietary GLA (mg/d) and AA 
(mg/d) are summarized in Tables 4 and 5. If a study met the eligibility criteria and contained 
more than one comparison, each comparison was reported as a separate data point. 
Baseline tissue AA levels were defined as relative abundance of AA in tissue 
phospholipids prior to dietary supplementation (or reduction) of the corresponding dietary n-6 
PUFA of interest (i.e., LA, GLA or AA). In the case of cross-over designs, baseline fatty acid 
composition was established following a washout period or after supplementation of a control 
diet if there were no or only minor changes in the dietary  n-6 PUFA content. For example, a 
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supplement rich in oleic acid (a monounsaturated fatty acid typically used as a control and 
known to have a neutral effect on tissue AA content) could be used as a control lipid (or oil) 
prior to supplementation of an equal amount of a lipid (or oil) rich in LA. Percent change for 
each dietary n-6 fatty acid of interest was used to standardize the relative differences between 
baseline intakes and intervention intakes following the experimental period using the following 
formula:  
intervention intake  -  baseline intake  x 100 
                     baseline intake 
The levels of intake were based on the relative caloric amount (% of calories), and when this data 
was not available absolute intake levels (mg/g or g/d) were used. Percent change for tissue AA 
content was used to standardize the relative differences between baseline levels and intervention 
levels following the experimental period using the following formula:  
post-intervention content  -  baseline content  x 100 
                     baseline content 
Statistical Analysis 
The overall linear correlation between percent change of dietary n-6 fatty acids and 
percent change of tissue AA was computed using the Proc Corr procedure in SAS 9.2 (SAS 
Institute Inc. SAS Campus Drive, Cary, North Carolina). The correlation matrix and the T 
statistic tested for correlation and statistical significance, respectively. For the linear correlations, 
the equation of the line was computed, and represented in y=mx+b for those that exhibited 
linearity. Data not resembling a linear relationship (i.e. dietary GLA and AA) utilized a 
polynomial growth curve from SAS General Linear Model and t-tests for model parameters 
tested for significance.  P-values less than or equal to 0.05 were considered significant. The Y 
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values represent changes of AA (% from baseline) and the X values represent the changes of the 
various dietary n-6 PUFA (% from baseline or mg/g supplemented).  In addition to the overall 
correlation test, the statistical significance for each individual data point (for changes in tissue 
AA), as reported by the authors in their respective manuscripts, was identified in each graph. If 
the changes from baseline were significantly different the data was represented by triangle. If the 
changes from baseline were not statistically different, they were represented by a diamond. 
Results 
Twelve comparisons reported decreases in LA intakes (-12% to -90%) and no significant 
correlations were associated with changes in plasma/serum phospholipid AA content (r2=0.05, 
p=0.44, y= (-0.090*x)-6.56) (Figure. 4 and Table 1). Only one study of the twelve reported a 
significant change, a 4.1% increase in AA content, following a 29% reduction in LA intake 
(113).  
Increases in dietary LA, ranging from 12%-550%, were not significantly correlated with 
changes in plasma/serum phospholipid AA content (r2=0.03, p =0.45, y= (-0.002*x)-0.09) 
(Figure. 5 and Table 1). Of the seventeen comparisons, only four studies reported significant 
changes in AA levels when dietary LA levels were increased; three studies reported 3-20% 
reductions following 12%-110% increases in LA consumption (103, 113, 114) and only one 
study reported a significant increase in AA content (10%) following an 86% increase in LA 
intake (114). Sub-dividing the studies by design (crossover versus non-crossover) had no effect 
on the results (data not shown). Similarly, in those studies that only reported absolute levels of 
LA supplementation (g/d), increasing LA supplementation was not significantly correlated with 
changes in plasma/serum phospholipid AA content (r2=0.06, p=0.64, y=( 0.793*x)+1.17) 
(Figure. 6 and Table 2). Of the fourteen comparisons, only two were significantly different, one 
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resulted in an increase in AA content by 3% following supplementation of 2.24 g/d of LA (115) 
and the other resulted in a reduction of AA content by 7% following supplementation of 0.86 g/d 
(116).  
 Similar comparisons were made in erythrocytes with increasing and decreasing intakes of 
LA, although the number of studies were more limited. Increases in dietary LA, ranging from 
12%-100%, were not significantly correlated with changes in tissue AA content (r2=0.06, 
p=0.75, y = (- 0.133*x)-1.24) (Figure. 7). Reducing dietary LA intake (-12% to -70%) was not 
significantly correlated with changes in tissue AA content (r2=0.02, p=0.77, y = (-
0.014*x)+0.17) (Figure. 8). In addition, out of the seven studies, only one study reported a 
significant change where decreasing dietary LA intake by 29% resulted in a 4% increase in AA 
content (113).  
 Seven studies met our criteria for the effects of GLA supplementation on changes in 
plasma/serum phospholipid AA content (Figure. 9). There appeared to be a dose dependent 
increase in AA content with increasing intakes of GLA (ranging from 360-6000 mg/day). This 
positive correlation (r²=0.75, p=0.03, y= (0.004*x)+7.36) was significant with a linear regression 
model, but not with a non-linear (polynomial) regression model (p=0.19). Of the six AA data 
points, four of them reported statistically significant increases.   
 Similiarly, increasing dietary AA (0.5 g/d to 6 g/day) was positively correlated with 
increases in plasma/serum phospholipid AA content using a linear regression model (r²=0.83, 
p=0.02, y= (0.018*x)+38.60) (Figure. 10), but not with a non-linear (polynomial) regression 
model (p=0.16). All data points were reported as significantly different (Table 4).
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Table 1.  Studies outlining the effects of decreasing dietary linoleic acid levels (% energy) from baseline on changes in plasma/serum phospholipid arachidonic acid content
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Author, 
(reference)    
Study design Subjects               Diet length Diet comparison LA (% change)  
Baseline to 
intervention                                     
∆AA (%) 
change 
  Comments           
Lichtenstein (117) Randomized 
double-blind 
crossover  
N=30 35 days Soybean oil diet 
(baseline) compared 
to high oleic acid 
soybean oil diet 
 
 
 
-82 
(11%-1.9%) 
N.S. Pooled data of men and women. Baseline diet of 10.96% 
energy closest to DRI for LA. AA did not differ among 
remaining groups tested either 
 
Lasserre (103) Randomized 
crossover 
N=24 5 months Peanut oil diet 
(baseline)  compared 
to milk fat diet 
 
Peanut oil diet 
(baseline) compared 
to low erucic acid 
rapeseed oil (canola 
oil)  diet 
-90 
(6.5%-0.6% ) 
 
 
 
-30 
(6.5%-4.5%) 
N.S. 
 
 
 
 
 
N.S. 
 
Used peanut oil group b/c close to DRI for LA. Subjects 
were nuns in monastery.  
 
 
 
Used peanut oil group b/c close to DRI for LA. Subjects 
were nuns in monastery.  
 
Liou (118) Randomized 
crossover 
N=24 4 weeks High linoleic 
sunflower oil (diet) 
compared to high 
oleic acid safflower 
oil (diet) 
-63 
(10.5%-3.8%) 
N.S. Incorporated test oils into baked foods (cookies, breads), 
mayonnaise, salad dressing. AA data presented in graphs, 
not tables. Fish intake was avoided for all groups. AA PL 
content did not differ between sequence of diets going 
from high LA to low LA or vice versa. Study address low 
or high LA with constant ALA at 1% 
 
Vega-Lopez (119) Randomized 
crossover 
N=15 35 days Canola oil diet 
compared to palm 
oil diet 
 
-50 
(6.5%-3.3%) 
N.S. Canola oil in mixed foods was replaced by palm oil in 
mixed foods.  
AA did not change among all three dietary groups. 
Canola oil diet is baseline because closest to DRI LA 
intake.  
Geppert (120) Randomized 
double- blind  
intervention  
N=54 8 weeks Baseline diet 
compared to LA 
reduced diet (using 
olive oil capsules) 
-12 
(5.8%-5.1%) 
N.S. Used olive oil capsules with vegetarians. 
King (113) Randomized 
parallel 
N=66 6 weeks Baseline diet 
compared to low fat 
diet.  
-29 
(10%-7.1%) 
+4.1a Used modified food items for diets containing different 
amounts of fat. Reported AA PL in % change.  
 
Li (122) Parallel 
intervention  
N=17 28 days High LA diet to 
moderate LA diet 
using canola 
oil/canola margarine 
 
-48 
(13.5%-7%) 
 
 
  
N.S 
 
 
 
 
Subjects were given diet more than twice DRI for LA and 
then given diet resembling the DRI for LA. All groups 
were asked to not consume fish.  
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aPercent change (±) from baseline in AA that is significant (p<0.05). Non-significance is denoted by N.S. 
Abbreviations: AA, arachidonic acid; DRI, Dietary Reference Intake; LA, linoleic acid  
High LA diet to 
normal LA diet 
using canola 
oil/canola margarine 
 
-39 
(11.9%-7.3%) 
 
 
  
          N.S. 
 
 
 
Mantzioris (123) 
 
Parallel 
intervention 
N=15 4 weeks Control diet 
(sunflower oil) 
group compared to 
intervention diet 
(flaxseed oil) 
-57 
(7.8%-3.3%) 
N.S. Control group consumed relatively close to DRI for LA 
while intervention group reduced LA by more than half. 
Goyens (121) Double-blind 
intervention  
N=19 6 weeks Reduced LA in food 
items (margarines, 
pastries, baked 
goods)  
-57 
(7%-3%) 
N.S. Test oils consumed in margarine and pastries.  Prohibited 
consumption of fish or marine foods in all groups.  
28 
 
 Table 2.  Studies outlining the effects of supplementing dietary linoleic acid levels (g/day) on changes in plasma/serum phospholipid arachidonic acid content. 
Author, 
(reference) 
Study design Subjects Diet length Diet comparison LA  
(% change) 
Baseline to 
intervention                              
∆ AA (%) change Comments 
Thijssen (124) Randomized multiple 
crossover 
N=45 
 
5 weeks Stearic acid  diet to 
oleic acid diet in 
food items (using 
margarines, breads, 
sponge cakes) 
 
Oleic Acid to 
Linoleic Acid food 
items (margarines, 
breads, sponge 
cakes) 
 
14 
(2.1% -2.4%) 
 
 
 
 
 
287 
(2.4%-9.3%) 
N.S. 
 
 
 
 
 
 
N.S. 
No order to diets 
given. Subjects 
received all 3 diets 
with varying 
amounts of LA.   
 
 
 
Lichtenstein (117) Randomized 
double-blind 
crossover 
N=30 35 days Baseline soybean oil 
diet compared to 
Low saturated fat-
soybean oil diet. The 
soybean oils varied 
in linoleic acid 
composition 
 
Baseline high oleic-
soybean oil diet to 
low ALA-soybean 
oil diet 
15.8 
(11% -12.7%) 
 
 
 
 
 
 
552 
(1.9 %-2.5%) 
N.S. 
 
 
 
 
 
 
 
N.S. 
 
Pooled data of men 
and women. Five 
diets of random 
order. Subjects 
visited metabolic 
kitchen 3 times 
week. Varying LA 
amounts using 
modified soybean 
oils.  
Vega-Lopez (119) 
 
Randomized 
crossover  
 
 
 
 
 
 
N=15 
 
35 days Canola oil diet 
compared  to 
soybean oil diet 
64.2 
(6.5%-10.7%) 
N.S. Canola oil in mixed 
foods was replaced 
by soybean oil in 
mixed foods. AA did 
not change among all 
three dietary groups. 
Canola oil diet is 
baseline because 
close to the DRI for 
LA. 
 
 
29 
Liou (118) Randomized 
crossover  
N=22 
 
4 weeks Low LA diet (high in 
oleic acid safflower 
oil) compared to high 
LA diet (high in 
sunflower oil) 
176 
(3.8%-10.5%) 
N.S. AA PL content 
presented as graphs, 
not numerically. Fish 
was avoided in all 
dietary groups. ALA 
intake was kept 
constant between 
low/high diet 
  
 
Valsta (96) Randomized 
crossover  
N=39 
 
6 weeks Habitual diet 
compared to high 
linoleic acid 
trisunflower oil diet.  
86 
(4.2%-7.8%) 
+10 Fish cut in half in all 
dietary groups. Has a 
baseline for before 
each diet. Used 
trisunflower oil in 
margarine, food oil, 
salad dressing, bread, 
cake and cookies, in 
place of habitual 
foods.  
 
Raatz (114) Randomized 
crossover  
N=10 
 
28 days Low fat diet (20% 
energy) compared to 
high fat diet (45% 
energy).  
 
100 
(6%-12%) 
-16 Modified foods rich 
in linoleic acid. 
Random order to 
diet, so baseline was 
chosen based on DRI 
of LA. Used washout 
period of 21-28 days 
Lasserre (103) Randomized 
crossover 
N=24 
 
5 months Peanut oil diet 
compared to 
sunflower oil 
111 
(6.5%-13.7%) 
-20 Used peanut oil 
group b/c close to 
DRI for LA.  
Innis (111) 
 
Randomized 
crossover  
 
N=24 
 
8 weeks 
 
Low LA diet  to high 
LA diet 
 
176 
(3.8%-10.5%) 
 
N.S. 
 
Controlled for 
dietary AA. 
 
King (113) Randomized parallel  
intervention 
N=33 6 weeks Baseline diet 
compared to 
moderate fat diet. 
13 
(10.3%-1.6%) 
-3.2a Used modified food 
items for diets 
containing different 
amounts of fat. 
Reported AA PL as 
% change.  
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aPercent change (±) from baseline in AA that is significant (p<0.05). Non-significance is denoted by N.S. 
Abbreviations: AA, arachidonic acid; DRI, Dietary Reference Intake; LA, linoleic acid  
 
 
 
 
Li (122) Parallel intervention  N=10 
 
 
 
 
 
 
 
N=7 
 
 
14 days 
 
 
 
 
 
 
 
14 days 
Baseline Western 
diet to intervention 
diet increased in LA 
intake using 
safflower oil 
 
 
Baseline Western 
diet to intervention 
diet increased in LA 
intake using 
safflower oil 
 
17.8 
(10.1%-1.9%) 
 
 
 
 
 
 
82.4 
(7.4%-13.5%) 
N.S. 
 
 
 
 
 
 
 
 
N.S. 
Used safflower 
oil/safflower 
margarine to increase 
LA in diet to almost 
twice DRI of LA. 
AA did not differ 
among all groups in 
study.  
 
 
Montoya (125) 
 
Sequential 
interventions  
N=41 
 
4 weeks From palm oil based 
diet compared to 
olive oil based diet. 
 
Olive oil based diet 
to sunflower oil base 
diet 
16 
(3.2%-3.7%) 
 
 
229.8 
(3.7%-12.2%) 
N.S. 
 
 
 
N.S. 
Used nuns and 
priests. Everyone 
consumed same 
sequence of diets.  
AA did not change 
among the three test 
diets. No crossover, 
subjects were their 
own controls. 
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Table 3.  Studies outlining the effects of supplementing dietary linoleic acid levels (g/day) on changes in plasma/serum phospholipid arachidonic acid content. 
 
Author, 
(reference) 
Study design Subjects Diet length LA source, amount  supplemented (g/d) ∆ AA (%) change Comments 
Thies (127) 
 
Randomized, double-blind, parallel 
intervention 
 
N=8 12 weeks 
 
Oil blend (0.64) 
 
 
Placebo oil (0.9) 
 
 
N.S. 
 
 
N.S. 
 
 
Different oil blends were 
sources of LA 
Geppert (116) 
 
Randomized double- blind parallel 
intervention  
 
N=20 8 weeks 
 
Oil blend (0.86) 
 
-7a 
 
Blend palm, rapeseed and 
sunflower oil 
Johansson (128) 
 
Randomized, double-blind, crossover 
 
N=12 4 weeks 
 
Sea buckthorn berry oil (0.90) 
 
N.S. 
 
Sea buckthorn berry oil is 
17.9% LA 
Kew (129) 
 
Double-blind, parallel intervention 
 
N=42 4 weeks 
 
Olive oil (0.92) 
 
N.S. 
 
 
Buckley (130) Double-blind parallel intervention 
 
N=45 
 
 
4 weeks 
 
Olive oil (0.95) 
 
 
N.S. 
 
 
 
Yaqoob (131) 
 
Randomized, double- blind parallel  
intervention 
N=8 per 
group 
12 weeks 
 
Placebo (coconut/soybean oil) (1.0) 
 
Olive oil (1.2) 
 
Sunflower oil (6.95) 
N.S. 
 
 
N.S. 
 
N.S. 
 
 
 
Wallace (132) 
 
Randomized, double- blind  parallel 
intervention 
 
 
N=8 
 
 
N=8 
12 weeks 
 
Oil blend (1.52) 
 
 
palm/soybean oil (1.7) 
 
N.S. 
 
 
N.S. 
 
 
 
Miles (133) 
 
Randomized, double-blind parallel 
intervention  
N=8 12 weeks 
 
Placebo (palm/sunflower oil) (2.07) 
 
N.S. 
 
 
 
Grimsgaard (115) 
 
Double-blind, parallel intervention 
 
n=78 7weeks 
 
Corn oil (2.24) 
 
+3.1 
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Conquer (134) 
 
Double-blind, parallel intervention N=24 42 days 
 
Corn oil (2.39) 
 
N.S. 
 
 
 
Finnegan (135) 
 
Double-blind, parallel intervention 
 
N=50 6 months 
 
Safflower/sunflower  (11.6) 
 
N.S. 
 
Test oils provided as 
margarine and capsules 
Anderson (126) 
 
Parallel intervention 
 
N=8 
 
 
N=9 
3 months 
 
Olive oil (0.2) 
 
 
Olive oil (0.2) 
 
N.S. 
 
 
N.S. 
 
Olive oil supplement 
 
Provided LA for two 
different groups 
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Table 4.  Studies outlining the effects of supplementing dietary gamma-linolenic acid on changes in plasma/serum phospholipid arachidonic acid content. 
 
Author, (reference) Study design Subjects Diet length GLA source,  amount 
supplemented (mg/d) 
∆ AA (%) 
change 
Comments 
Thavonen (126) 
 
Randomized, double-
blind crossover 
 
N=15 3 weeks Black current seed oil (378) N.S. 
 
Subjects aged 55-75 years old. 
Mills (127) 
 
Randomized double-
blind parallel 
intervention 
N=10 28 days Borage oil (1300) +12 
 
AA data available for only pre 
and post intervention (28 days). 
Miles (128) 
 
Randomized double-
blind intervention 
N=8-12 12 weeks Borage oil capsules (2000) 
 
+15 
 
Consumed capsules for 12 
weeks. AA only increased after 
the 8th week, no difference 
after 8th week.  
Theis (129) 
 
Double-blind parallel 
interventions 
N=8 12 weeks GLA-rich triacylglycerol capsules 
(770) 
+27a 
 
Subjects consumed capsules for 
12 weeks. AA changed only on 
12th week. 
Yaqoob (130) 
 
Double-blind parallel 
intervention  
 
N=8 12 weeks Evening primrose oil (1062) 
 
N.S. 
 
 
Ebden (131) 
 
Double-blind 
intervention 
N=6 8 weeks Efamol oil (360) 
 
N.S. 
 
No crossover with placebo. 
Subjects were asthmatics used 
medication or bronchodilator.  
Johnson (132) 
 
Pre-post intervention N=5 3 weeks Ultra-GLA capsules (6000) 
 
 
+31 
 
 
 
aPercent change (±) from baseline in AA that is significant (p<0.05). Non-significance is denoted by N.S. 
Abbreviations: AA, arachidonic acid; GLA, gamma-linolenic acid 
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Table 5.  Studies outlining the effects of supplementing dietary arachidonic acid on changes in plasma/serum phospholipid arachidonic acid content. 
 
Author, 
(reference) 
Study design Subjects Diet length AA source, amount 
supplemented (mg/d) 
∆ AA (%) 
change 
Comments 
Ishikura (133) 
 
Double-blind crossover 
 
N=25 1 month SUNTGA40S capsules (720) 
 
+27 
 
Derived from Mortierella alpina 
Nelson (134) 
 
Single blind crossover 
intervention 
 
N=10 50 days ARASCO (1490) 
 
+85 Had 65 day washout period. 
Derived from Mortierella alpina 
Theis (129) 
 
Randomized, double-
blind, parallel 
intervention 
N=48 12 weeks  ARASCO (680) 
 
+85 
 
Derived from Mortierella alpina 
Theis (129) 
 
Randomized, double-
blind, parallel 
intervention 
N=48 12 weeks  ARASCO (680) 
 
+85 
 
Derived from Mortierella alpina 
Kusmoto (135) 
 
Double-blind 
intervention  
 
N=12 4 weeks SUNTGA40S (838) 
 
+45 
 
Derived from Mortierella alpina 
Sinclair (136) Parallel intervention N=4 7 days White meat/eggs  
 
 
 
+52a 
 
Consumed AA rich, low fat 
diet. 
Seyberth (59) 
 
Single blind 
intervention 
 
N=4 2-3 weeks, 
depending upon 
subject 
Capsules, AA ethyl ester (6000) 
 
+136 
 
Averaged from all 4 subjects. 
 
aPercent change (±) from baseline in AA that is significant (p<0.05). Non-significance is denoted by N.S. 
Abbreviations: AA, arachidonic acid 
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2. Discussion  
Arachidonic acid is arguably the most important PUFA associated with membrane 
phospholipids. Upon release, AA can be enzymatically metabolized to a surfeit of bioactive 
derivatives, eicosanoids, known to contribute to a variety of chronic diseases (48, 75, 107, 108). 
The relative abundance of AA in membrane phospholipids positively influences eicosanoid 
production (137). It is well known that dietary PUFA can affect tissue AA levels; however, what 
is uncertain and wrought with controversy is whether modifying current intakes of dietary LA 
will result in concomitant changes in tissue AA content. Therefore, if the public chose to 
consume less LA, would tissue AA levels go down, and antithetically, if the public consumed 
more LA would tissue levels of AA go up? The goal of this paper was to ascertain the 
relationship between dietary LA and tissue AA content in adults consuming a Western-style 
background diet. It was not designed to address other controversies surrounding the issues of 
dietary PUFA or in other population groups. 
Many papers interchange the more general term n-6 PUFA for dietary LA, but there are 
two major n-6 PUFA, LA and AA, and they are distributed unevenly in the Western diet. While 
LA is the major PUFA in almost every commonly consumed food, AA is exclusively found in 
animal products, such as, muscle, organ meats and eggs (138). They have distinct biological 
activities that are biochemically linked via desatuation and elongation, and as such, LA is the 
conditionally essential fatty acid. Linoleic acid is specifically required in the skin to maintain the 
integrity of the epidermal water barrier and AA is the immediate precursor to eicosanoids, as 
well as being the n-6 PUFA selectively incorporated into the membranes of certain tissues, i.e., 
brain (139). When consumed (LA vs. AA) they appear to have differential effects on tissue fatty 
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acid composition, where AA appears to more robustly modify tissue AA levels and eicosanoids 
(112, 140). 
The data presented in this paper does not suggest that a dose response between dietary 
LA and tissue AA exists within the backdrop of individuals consuming a Western-type diet. 
Increasing LA by up to 551% and reducing LA by as much as 90% failed to yield compelling 
evidence supporting the concept that any conversion of dietary LA to downstream metabolites 
results in tissue enrichment of AA, a notion commonly asserted (105). We chose to evaluate the 
data by looking at changes from baseline in tissue AA content to standardize the data from one 
study to the next. Each study began with a baseline value and we reported percent changes from 
that baseline. Supplemental intakes of LA were reported based on energy and when that value 
could not be determined, we reported absolute supplemented values, and these data were 
reported separately.  
As observed from the distribution of the responses, there was wide variability. Some 
papers showed small increases in tissue AA levels when dietary LA changed, while other papers 
showed small decreases, but most of these changes lacked significance. When there was 
significance, the changes were minimal and the distribution pattern of the data did not favor an 
increase or a decrease. We chose plasma/serum and erythrocytes as the tissues of choice because 
here is where the plethora of data exists in the human literature.  Erythrocytes are a more stable 
pool of dietary lipids, contain very little neutral lipids and thus represents a membrane fraction of 
AA. Fasting plasma/serum phospholipid levels primarily (but not exclusively) represents the 
membranes of lipoproteins derived from the surface of hepatic endoplasmic reticulum, and this 
pool is more responsive to more recent dietary PUFA intakes.  
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In an effort to identify why dietary LA may not modify tissue AA levels, we reviewed the 
literature for dietary GLA using the same search strategy. Was the conversion of LA to AA rate-
limiting, or were tissue levels of AA saturated? Delta-6 desaturase is the rate-limiting enzyme in 
the metabolism of LA to AA. GLA is a dietary n-6 PUFA that enters the metabolic pathway after 
the delta-6 desaturase step. If delta-6 desaturase is rate-limiting and tissue AA content is not 
saturated, then there should be evidence that including GLA in the diet increases tissue AA 
levels. When GLA was supplemented as the triacylglycerol form or as a component of a dietary 
oil containing GLA (i.e., blackcurrant, evening primrose or borage oil), tissue AA content 
increased in a dose responsive manner. These effects appeared to be less prominent in those 
studies (126-128) that used oils containing appreciable amounts of the more highly unsaturated 
n-3 PUFA stearidonic acid, i.e., blackcurrant or borage oil (138). When AA was supplemented in 
the diet, there was further enrichment in tissue AA content above that observed with either LA or 
GLA. These results suggest that delta-5 desaturase potentially becomes rate limiting when GLA 
is supplemented. The reaction mediated by delta-5 desaturase is an intermediate step between 
GLA and AA and by-passing that step with dietary AA leads to further enrichment. These data 
seem to suggest that while dietary LA maybe a metabolic precursor for AA, its influence on 
tissue levels are limited by the enzymatic conversion through delta-6 desaturase and not due to 
tissue saturation of AA. This data is supported by the poor rates of conversion of plasma/serum 
LA to AA in adults. In tracer studies involving stable isotopes, the estimated fractional 
conversion of LA to AA was between 0.3% and 0.6% (141). 
The levels of LA in the diet to achieve essentiality could be as low as 0.5-2.0% of energy 
in infants (13, 94) and it has been reported that tissue levels of AA no longer respond to dietary 
LA intakes above 2% energy in adults (95). Our study was designed to choose studies that 
38 
incorporated a Western-type diet where LA is not typically limiting, reflective of the general 
public. This means a full complement of PUFAs were being consumed along with LA 
supplementation. The DRIs for LA and ALA are 12g-17g/d and 1.1g-1.6g, respectively (women 
the lower figure, men the higher figure). This would be equivalent to intakes approximating 6% 
and 0.7% of calories per day for LA and ALA, respectively. It is not unreasonable to think that 
with a background diet containing LA, ALA, AA, and long-chain n-3 PUFAs, i.e. 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at typical intakes, that modifying 
LA levels may not influence tissue AA levels.  
A few studies specifically evaluated the impact of dietary LA on tissue AA and failed to 
observe a positive relationship (111, 112).  For example, by maintaining constant intake of ALA 
and increasing LA levels from 3.8% energy to 10.5% energy using LA-rich oils,  LA was 
inversely associated with tissue AA levels (p<0.001) (47). These results were consistent with 
another study that reported an inverse relationship between dietary LA and tissue AA (112). This 
latter paper was not included in our review because it did not meet all of our inclusion/exclusion 
criteria, nevertheless it clearly showed that dietary LA does not increase tissue AA content. A 
number of studies included in this analysis also reported significant inverse relationships (103, 
113, 114, 116). The data suggests that as LA increases in the diet, it maybe be competing with 
AA for reacylation into phospholipids.   
A small number of studies modified LA intakes by using oils that also contained some 
ALA, such as soybean and canola oil (103, 117, 119), but the results from these studies were not 
significant and were similar to the other results. It must be remembered that soybean oil has a 
LA:ALA ratio similar (8:1) to that found in the US diet (10:1). We also included two studies that 
supplemented LA with recommended fish restrictions (because they met our inclusion/exclusion 
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criteria) (96, 118).  One study (+176% LA) reported no changes in AA levels, while the other 
(+86% LA) reported a 10% increase in AA.  
Some of the weaknesses of this review are reflected in the studies that qualified for our 
evaluation. Most were not designed to specifically address our research question; however, those 
that were specifically designed to evaluate the effect of dietary LA on tissue AA content yielded 
results that were similar to the overall results (111). Each study used a different population with 
potentially different background diets, but this would better reflect the consumption patterns of 
the general public. Not all studies were blinded (61% were blinded) and dietary LA was not 
exclusively modified. The methods for modifying LA intakes were varied and other dietary 
PUFA were not controlled for with the exceptions identified previously, and data for only two 
tissues were evaluated. When LA was modified, it was done so by typically changing the levels 
of an oil rich in LA (i.e., corn oil, safflower oil, sunflower oil) or foods containing LA (as 
opposed to adding pure LA), reflecting how the LA would be consumed by the general public. 
There was no standard length to the studies. For example, studies involving plasma/serum ranged 
between 14 days-5 months, and those looking at erythrocyte data ranged between 14-180 days. 
Importantly, the subjects were used as their own controls, the studies addressed changes in LA in 
relationship to Western-type diets, and the results were not different between those studies that 
were double-blind randomized placebo controlled trials (1/3) and those that were not. Despite 
these weaknesses, positive results were still identified with intakes of GLA and AA, helping to 
support those results reported with LA. 
In summary, elevated tissue AA levels are believed to be positively associated with 
eicosanoid formation and risk for a variety of chronic diseases, including cardiovascular disease, 
cancer and inflammation. The literature expresses concern over the fact that increasing dietary 
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LA can potentially enrich tissues with AA due to their metabolic link. The results of this study 
do not support this concern. There is insufficient evidence to suggest that changes in dietary LA 
will modify tissue AA content in an adult population consuming a Western-type diet. 
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AA is arguably the most important PUFA associated with membrane phospholipids.  
Upon release, it can be enzymatically converted to potent bioactive lipid molecules called 
eicosanoids. Eicosanoids are linked to a variety of chronic diseases such as CVD, cancer and 
inflammation (48). Furthermore, tissue AA abundance is directly correlated with eicosanoid 
production (14). What is less understood and more controversial is the impact of dietary 
precursors of AA (i.e. LA) on changes in tissue AA content. The literature expresses concern 
with regards to the high n-6 PUFA content in the Western diet, viz., LA, and how high intakes 
might lead to further enrichment of AA in tissues and subsequent eicosanoid production (150). 
As such, to lower tissue AA levels, recommendations emphasize reducing the levels of LA in the 
diet. To address this concern, a review of the literature regarding this issue may provide insight 
as to whether tissue AA is modified by dietary precursors (i.e. LA).  
Studies involving dietary interventions that modified LA intake were sought from the 
literature. The initial search produced 4336 abstracts. Using our inclusion/exclusion criteria, 293 
articles were retained and further reviewed. Eventually, 36 articles met all necessary criteria for 
retention.  Data on LA supplementation was analyzed as % change based on calories (increasing 
or decreasing from baseline) or the levels supplemented (g/d).  
 The results demonstrated that no significant correlations were found between changes in 
LA consumption and changes in tissue AA content when expressing the data based on % calories 
increasing or decreasing) or g/d supplementation. Two possible reasons could explain the results, 
(i) feedback inhibition on the conversion of LA to AA via the delta-6 desaturase step, and/or (ii) 
tissue saturation of AA. To address these possibilities, we investigated articles that supplemented 
GLA in the diet.  GLA is an n-6 PUFA that is introduced after the delta-6 desaturase step. By 
supplementing diets with GLA, it resulted in AA enrichment in tissue phospholipids, suggesting 
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the ability of dietary LA to modify tissue AA was being controlled by the delta-6 desaturase step. 
When AA was supplemented to the diet, further enrichment occurred, suggesting subsequent 
secondary regulatory steps (i.e., delta-5 desaturase) are involved in AA formation from 
precursors.  
In conclusion, these results indicate there is insufficient evidence to suggest that tissue 
AA content is affected by changes in LA intake in the context of a Western diet. This affect 
appears to be based on feedback inhibition of delta-6 desaturase. However, by-passing this 
regulatory step with dietary GLA results in further enrichment of AA, apparently regulated by 
delta-5 desaturase. And finally, of all the n-6 PUFA in the diet, tissues are most responsive to 
dietary AA.  
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Figure 4: Effects of decreasing dietary linoleic acid (LA) intake (% change) based on energy on 
changes in plasma/serum phospholipid arachidonic acid (AA) content. Significant changes 
(p<0.05) in AA as reported in the original papers are designated as triangles. Non-significant AA 
changes as reported in the original papers are designated as diamonds. Abbreviations: AA, 
arachidonic acid; LA, linoleic acid; PL, phospholipid.  
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Figure 5: Effects of increasing dietary linoleic acid (LA) intake (% change) based on energy on 
changes in plasma/serum phospholipid arachidonic acid (AA) content. Significant changes 
(p<0.05) in AA as reported in the original papers are designated as triangles. Non-significant AA 
changes as reported in the original papers are designated as diamonds. Abbreviations: AA, 
arachidonic acid; LA, linoleic acid; PL, phospholipid.   
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Figure 6: Effects of increasing dietary linoleic acid (LA) intake (g/d) on changes in 
plasma/serum phospholipid arachidonic acid (AA) content. Significant changes (p<0.05) in AA 
as reported in the original papers are designated as triangles. Non-significant AA changes as 
reported in the original papers are designated as diamonds. Abbreviations: AA, arachidonic acid; 
LA, linoleic acid; PL, phospholipid. 
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Figure 7: Effects of increasing dietary linoleic acid (LA) (% change) intake based on energy on 
changes in erythrocyte (RBC) phospholipid arachidonic acid (AA) content. Significant changes 
(p<0.05) in AA as reported in the original papers are designated as triangles. Non-significant AA 
changes as reported in the original papers are designated as diamonds. Abbreviations: AA, 
arachidonic acid; LA, linoleic acid; PL, phospholipid. 
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Figure 8:  Effects of decreasing dietary linoleic acid (LA) (% change) based on energy on 
changes in erythrocyte (RBC) phospholipid arachidonic acid (AA) content. Significant changes 
(p<0.05) in AA as reported in the original papers are designated as triangles. Non-significant AA 
changes as reported in the original papers are designated as diamonds. Abbreviations: AA, 
arachidonic acid; LA, linoleic acid; PL, phospholipid. 
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Figure 9: Effects of increasing dietary gamma-linolenic acid (GLA) (mg/d) on changes in 
plasma/serum phospholipid arachidonic acid (AA) content. Significant changes (p<0.05) in AA 
as reported in the original papers are designated as triangles. Non-significant AA changes as 
reported in the original papers are designated as diamonds. Abbreviations: AA, arachidonic acid; 
GLA, gamma-linolenic acid; PL, phospholipid 
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Figure 10: Effects of increasing dietary arachidonic acid (AA) (% change) based on energy on 
changes in plasma/serum phospholipid AA content. Significant changes (p<0.05) in AA as 
reported in the original papers are designated as triangles. Non-significant AA changes as 
reported in the original papers are designated as diamonds. Abbreviations: AA, arachidonic acid; 
PL, phospholipid. 
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